Top

Published in:

01-08-2013 | Original Article

Impact of Body Mass Index on Postoperative Outcome of Advanced Gastric Cancer After Curative Surgery

Authors: Yen-Shu Lin, Kuo-Hung Huang, Yuan-Tzu Lan, Wen-Liang Fang, Jen-Hao Chen, Su-Shun Lo, Mao-Chih Hsieh, Anna Fen-Yau Li, Shih-Hwa Chiou, Chew-Wun Wu

Published in: Journal of Gastrointestinal Surgery | Issue 8/2013

Abstract

Introduction

The impact of body mass index (BMI) on the outcome of advanced gastric cancer surgery is controversial. Between December 1987 and December 2006, a total of 947 advanced gastric cancer patients receiving curative resection with retrieved lymph node number >15 were studied and divided into three groups according to BMI (<25, 25–30, and >30 kg/m²).

Results and Discussion

With regard to comorbidities present prior to surgery, higher BMI patients were more likely to have heart disease, type 2 diabetes, and hypertension than lower BMI patients. Compared with BMI <25 kg/m², higher BMI patients had longer operative time and more surgery-related morbidity. Multivariate Cox proportional-hazard analysis showed that age, pathological T and N categories, and lymphovascular invasion were independent prognostic factors. The initial recurrence patterns, 5-year overall survival, and cancer-specific survival were similar among the three groups.

Conclusion

Only in stage III gastric cancer with BMI less than 25 kg/m² patients receiving total gastrectomy had a more advanced pathological N category and a worse prognosis compared to those receiving subtotal gastrectomy. Higher BMI was associated with longer operative time and more surgery-related morbidity than lower BMI. BMI alone is not an independent prognostic factor.

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569–578.PubMedCrossRef

Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, Wu XT. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer 2009; 45: 2867–2873.PubMedCrossRef

Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, Ito K, Akiyama S, Nakao A. Obesity and outcome of distal gastrectomy with D2 lymphadenectomy for carcinoma. Hepatogastroenterology 2004; 51: 1225–1228.PubMed

Inagawa S, Adachi S, Oda T, Kawamoto T, Koike N, Fukao K. Effect of fat volume on postoperative complications and survival rate after D2 dissection for gastric cancer. Gastric Cancer 2000; 3: 141–144.PubMedCrossRef

Dhar DK, Kubota H, Tachibana M, Kotoh T, Tabara H, Masunaga R, Kohno H, Nagasue N. Body mass index determines the success of lymph node dissection and predicts the outcome of gastric carcinoma patients. Oncology 2000; 59: 18–23.PubMedCrossRef

Barry JD, Blackshaw GR, Edwards P, Lewis WG, Murphy P, Hodzovic I, Thompson IW, Allison MC. Western body mass indices need not compromise outcomes after modified D2 gastrectomy for carcinoma. Gastric Cancer 2003; 6: 80–85.PubMed

Moriwaki Y, Kunisaki C, Kobayashi S, Harada H, Imai S, Kasaoka C. Does body mass index (BMI) influence morbidity and long-term survival in gastric cancer patients after gastrectomy? Hepatogastroenterology 2003; 50: 284–288.PubMed

Tsujinaka T, Sasako M, Yamamoto S, Sano T, Kurokawa Y, Nashimoto A, Kurita A, Katai H, Shimizu T, Furukawa H, Inoue S, Hiratsuka M, Kinoshita T, Arai K, Yamamura Y; Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group. Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extensive para-aortic D3 lymphadenectomy (JCOG9501). Ann Surg Oncol 2007; 14: 355–361.PubMedCrossRef

Kulig J, Sierzega M, Kolodziejczyk P, Dadan J, Drews M, Fraczek M, Jeziorski A, Krawczyk M, Starzynska T, Wallner G; Polish Gastric Cancer Study Group. Implications of overweight in gastric cancer: a multicenter study in a Western patient population. Eur J Surg Oncol 2010; 36: 969–976.PubMedCrossRef

10.

Gretschel S, Christoph F, Bembenek A, Estevez-Schwarz L, Schneider U, Schlag PM. Body mass index does not affect systematic D2 lymph node dissection and postoperative morbidity in gastric cancer patients. Ann Surg Oncol 2003; 10: 363–368.PubMedCrossRef

11.

Tokunaga M, Hiki N, Fukunaga T, Ohyama S, Yamaguchi T, Nakajima T. Better 5-year survival rate following curative gastrectomy in overweight patients. Ann Surg Oncol 2009; 16: 3245–3251.PubMedCrossRef

12.

Oh SJ, Hyung WJ, Li C, Song J, Rha SY, Chung HC, Choi SH, Noh SH. Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma. J Gastroenterol Hepatol 2009; 24: 475–479.PubMedCrossRef

13.

Huang KH, Lan YT, Fang WL, Chen JH, Lo SS, Hsieh MC, Li AF, Chiou SH, Wu CW. Initial experience of robotic gastrectomy and comparison with open and laparoscopic gastrectomy for gastric cancer. J Gastrointest Surg. 2012; 16(7):1303–10.PubMedCrossRef

14.

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003 Jan;26 Suppl 1:S5–20.

15.

Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK; American College of Cardiology Foundation/American Heart Asscoiation Tasl Force on Practice Guidelines. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010 21;122(25):2748–64. doi:10.1161/CIR.0b013e3182051bab. Epub 2010 Nov 15.

16.

Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003 ;21(11):1983–92.

17.

Sobin L GM, Wittekind C, eds. TNM Classification of Malignant Tumours In: 7th ed. International Union Against Cancer (UICC). New York: Wiley, 2009.

18.

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810–1820.PubMedCrossRef

19.

Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, Lin HJ, Li AF, Lui WY. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003; 27: 153–158.PubMed

20.

Freeman JB, Meyer PD, Printen KJ, Mason EE, DenBesten L. Analysis of gallbladder bile in morbid obesity. Am J Surg 1975; 129: 163–166.PubMedCrossRef

21.

Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347: 995–999.PubMedCrossRef

22.

Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745–748.PubMedCrossRef

23.

Nomura E, Sasako M, Yamamoto S, Sano T, Tsujinaka T, Kinoshita T, Furukawa H, Shimizu T, Hiratsuka M, Kobayashi O, Kurokawa Y, Tanigawa N; Gastric Cancer Surgical Study Group of the Japan Clinical Oncology Group. Risk factors for para-aortic lymph node metastasis of gastric cancer from a randomized controlled trial of JCOG9501. Jpn J Clin Oncol 2007; 37: 429–433.PubMedCrossRef

24.

Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 309–315.PubMedCrossRef

25.

Siewert JR, Bottcher K, Stein HJ, Roder JD, Busch R. Problem of proximal third gastric carcinoma. World J Surg 1995;19: 523–531.PubMedCrossRef

26.

Piso P, Werner U, Lang H, Mirena P, Klempnauer J. Proximal versus distal gastric carcinoma-what are the differences? Ann Surg Oncol 2000;7:520–525.PubMedCrossRef

27.

Tsou CC, Lo SS, Fang WL, Wu CW, Chen JH, Hsieh MC, Shen KH. Risk factors and management of anastomotic leakage after radical gastrectomy for gastric cancer. Hepatogastroenterology 2011; 58: 218–223.PubMed

28.

Lo CH, Chen JH, Wu CW, Lo SS, Hsieh MC, Lui WY. Risk factors and management of intra-abdominal infection after extensive radical gastrectomy. Am J Surg 2008; 196: 741–745.PubMedCrossRef

Title: Impact of Body Mass Index on Postoperative Outcome of Advanced Gastric Cancer After Curative Surgery
Authors: Yen-Shu Lin
Kuo-Hung Huang
Yuan-Tzu Lan
Wen-Liang Fang
Jen-Hao Chen
Su-Shun Lo
Mao-Chih Hsieh
Anna Fen-Yau Li
Shih-Hwa Chiou
Chew-Wun Wu
Publication date: 01-08-2013
Publisher: Springer US
Published in: Journal of Gastrointestinal Surgery / Issue 8/2013
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-013-2238-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impact of Body Mass Index on Postoperative Outcome of Advanced Gastric Cancer After Curative Surgery

Abstract

Introduction

Results and Discussion

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Results and Discussion

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2013

A Rare Case Presentation of a Symptomatic Omphalomesenteric Cyst in an Adult, 24-Year-Old Patient, Treated with Laparoscopic Resection

Surgical Approach to Cervical Esophagogastric Anastomoses for Post-esophagectomy Complications

Complete Clinical Response After Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary?

Defining the Learning Curve for Robotic-assisted Esophagogastrectomy

Extended Right Hepatectomy in a Liver with a Non-bifurcating Portal Vein: the Hanging Maneuver Protects the Portal System in the Presence of Anomalies

MLH1 as a Direct Target of MiR-155 and a Potential Predictor of Favorable Prognosis in Pancreatic Cancer